Stem Cell Transplant Effective for Children With ArthritisJanuary 2, 2025Musculoskeletal DisordersSurgery
FDA Approves Ustekinumab Biosimilar Steqeyma, the Seventh of Its KindDecember 19, 2024DermatologyGastroenterologyMusculoskeletal Disorders
Project’s Improvement in JIA Outcome Disparities Sets Stage for Further InterventionsDecember 9, 2024Rare DiseasesMusculoskeletal Disorders
Could Biomarkers Help to Detect Lung Disease Earlier in Systemic JIA?December 9, 2024PulmonologyRare DiseasesMusculoskeletal Disorders
JIA Treatment Has Increasingly Involved New DMARDs Since 2001November 4, 2024Musculoskeletal DisordersRare Diseases
US Experience With Infliximab Biosimilars Suggests Need for More Development IncentivesAugust 13, 2024DermatologyGastroenterologyMusculoskeletal Disorders
Pyzchiva Receives FDA Approval as Third Ustekinumab BiosimilarJuly 2, 2024Rare DiseasesMusculoskeletal DisordersDermatologyGastroenterology
First-line Canakinumab Without Steroids Shows Effectiveness for Systemic Juvenile Idiopathic ArthritisJune 26, 2024Rare DiseasesMusculoskeletal Disorders
FDA Approves Polyarticular JIA Indication for SarilumabJune 12, 2024Rare DiseasesMusculoskeletal Disorders
FDA Grants New Pediatric Arthritis Indications for UpadacitinibJune 7, 2024Rare DiseasesMusculoskeletal DisordersGastroenterologyDermatology
Durable Tocilizumab Responses Seen in Trial Extensions of Polyarticular and Systemic JIA SubtypesApril 16, 2024Rare DiseasesMusculoskeletal Disorders
Clinical Characteristics of Chronic Nonbacterial Osteomyelitis Can Predict Therapy Needs Over TimeApril 3, 2024Rare DiseasesMusculoskeletal Disorders
Visionary Surgery Saved Pitcher’s Arm. Now Even Children Get ItApril 2, 2024Musculoskeletal DisordersAdolescent Medicine
Early Biologic Initiation Linked to Rapid Improvement of JIA, Sustained RemissionApril 1, 2024Rare DiseasesMusculoskeletal Disorders
Second FDA-Approved Tocilizumab Biosimilar Has Intravenous, Subcutaneous FormulationsMarch 8, 2024Rare DiseasesMusculoskeletal Disorders
